Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

NCT00580385 | Active Not Recruiting

• 1 other identifier: 97-094
• Study Type: interventional
• Target: 763
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.

Conditions

Osteosarcoma

Keywords

BONE

Outcome Measures

Primary Outcomes (1)

• To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.

  2 years

Secondary Outcomes (1)

• To attempt to grow these tumor cells in short term culture to test the sensitivity of these cells to chemotherapeutic agents and to correlate cytotoxicity with biochemical and molecular studies.

  2 years

Study Arms (1)

1

EXPERIMENTAL

Other: Tissue Procurement

Interventions

Tissue Procurement OTHER

MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting

1

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients with a presumed or known diagnosis of a primary or secondary bone cancer or other solid tumor who are having or have had a biopsy or surgery to remove tumor for diagnostic or therapeutic reasons. No tumors will be obtained solely for research purposes.
• All adult patients (\> or = to 18 yrs.) will have given written informed consent.
• All minor patients (\<18 yrs.) will have given assent to the best of their ability to understand, and their parent or guardian will have given written informed consent

You may not qualify if:

• N/A

Sponsors & Collaborators

• Rockefeller University: collaborator
• Memorial Sloan Kettering Cancer Center: lead
• Hospital for Special Surgery, New York: collaborator
• Weill Medical College of Cornell University: collaborator
• Columbia University: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Osteosarcoma

Interventions

Tissue and Organ Procurement

Condition Hierarchy (Ancestors)

Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Intervention Hierarchy (Ancestors)

Health Services; Health Care Facilities Workforce and Services

Study Officials

• Carol Morris, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2007
• First Posted: December 24, 2007
• Study Start: August 1, 1997
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): August 1, 2027
• Last Updated: May 1, 2026

Record last verified: 2026-04

Locations

US (1)